INDICATION CRENESSITY (crinecerfont) is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).

This site is intended for US healthcare professionals only.
Crenessity logo, click to visit homepage
RESHAPE CAH MANAGEMENT THROUGH CRF1

CRENESSITY inhibits ACTH secretion at the source1

Watch the video to learn more about how CRENESSITY works in the CRF pathway.

CRF has been identified as a primary regulator of the HPA axis, including production of adrenal cortisol, aldosterone, and androgens.2,3

CRENESSITY is a potent and selective CRF1 receptor antagonist.1,4,5 By selectively blocking CRF binding to CRF1 receptors in the pituitary gland, CRENESSITY1:

  • Directly reduces ACTH
  • Reduces downstream production of androgens
Schematic showing how CRENESSITY selectively blocks CRF binding to CRF₁, which, in turn, reduces ACTH and androgensSchematic showing how cortisol deficiency in CAH leads to androgen excess
CRENESSITY improves androgen control and allows for GC dose reductions, enabling a transformational approach to managing CAH.1

Efficacy

Review outcomes from CRENESSITY clinical trials.

Get in Touch

Sign up to schedule a call or visit with a Neurocrine representative.

ACTH=adrenocorticotropic hormone; CRF=corticotropin-releasing factor; CRF1=corticotropin-releasing factor type 1; GC=glucocorticoid; HPA=hypothalamic-pituitary-adrenal; MOA=mechanism of action; MOD=mechanism of disease.

REFERENCES

  • Crenessity. Package insert. Neurocrine Biosciences, Inc. 
  • Schröder MAM, Claahsen-van der Grinten HL. Novel treatments for congenital adrenal hyperplasia. Rev Endocr Metab Disord. 2022;23(3):631-645. doi:10.1007/s11154-022-09717-w
  • Mallappa A, Merke DP. Management challenges and therapeutic advances in congenital adrenal hyperplasia. Nat Rev. 2022;18(6):337-352. doi:10.1038/s41574-022-00655-w
  • Gully D, Geslin M, Serva L, et al. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization. J Pharmacol Exp Ther. 2002;301(1):322-332. doi:10.1124/jpet.301.1.322
  • Fleck BA, Hoare SR, Pick RR, Bradbury MJ, Grigoriadis DE. Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor. J Pharmacol Exp Ther. 2012;341(2):518-531. doi:10.1124/jpet.111.188714

INDICATION

CRENESSITY (crinecerfont) is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

CRENESSITY is contraindicated in patients with hypersensitivity to crinecerfont or any excipients of CRENESSITY.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions. A hypersensitivity reaction, including throat tightness, angioedema, and generalized rash, occurred in a subject after 3 days of treatment with CRENESSITY. If a clinically significant hypersensitivity reaction occurs, initiate appropriate therapy and discontinue CRENESSITY.

Risk of Acute Adrenal Insufficiency or Adrenal Crisis with Inadequate Concomitant Glucocorticoid Therapy. Acute adrenal insufficiency or adrenal crisis, which is potentially life-threatening, can occur in patients with underlying adrenal insufficiency who are on inadequate daily glucocorticoid doses, especially in situations associated with increased cortisol need, such as acute intercurrent illness, serious trauma, or surgical procedures. Continue glucocorticoids upon initiation of and during treatment with CRENESSITY. Do not reduce the glucocorticoid dose below the dose required for cortisol replacement. Patients should continue to use stress dosing of glucocorticoids in cases of increased cortisol need.

ADVERSE REACTIONS

In adult patients, the most common adverse reactions (at least 4% for CRENESSITY and greater than placebo) are fatigue, headache, dizziness, arthralgia, back pain, decreased appetite, and myalgia.

In pediatric patients, the most common adverse reactions (at least 4% for CRENESSITY and greater than placebo) are headache, abdominal pain, fatigue, nasal congestion, and epistaxis.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Dosage Forms and Strengths:

CRENESSITY is available in 50 mg and 100 mg capsules, and as an oral solution of 50 mg/mL.

Please see full Prescribing Information.